electroCore, Inc. (ECOR)

Market Cap	26.40M
Revenue (ttm)	7.52M
Net Income (ttm)	-21.32M
Shares Out	71.17M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,012
Open	0.390
Previous Close	0.364
Day's Range	0.370 - 0.390
52-Week Range	0.195 - 0.700
Beta	0.93
Analysts	Buy
Price Target	2.51 (+576.73%)
Earnings Date	Mar 8, 2023

About ECOR

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaw...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: ECOR

Financial Performance

In 2021, electroCore's revenue was $5.45 million, an increase of 55.93% compared to the previous year's $3.50 million. Losses were -$17.22 million, -26.77% less than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for ECOR stock is "Buy." The 12-month stock price forecast is $2.51, which is an increase of 576.73% from the latest price.

Price Target

$2.51

(576.73% upside)

Analyst Consensus: Buy